Lake Street Advisors Group LLC Acquires 317 Shares of Boston Scientific Co. (NYSE:BSX)

Lake Street Advisors Group LLC increased its stake in Boston Scientific Co. (NYSE:BSX) by 4.3% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,629 shares of the medical equipment provider’s stock after acquiring an additional 317 shares during the quarter. Lake Street Advisors Group LLC’s holdings in Boston Scientific were worth $681,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. MONECO Advisors LLC raised its holdings in shares of Boston Scientific by 7.6% during the third quarter. MONECO Advisors LLC now owns 3,861 shares of the medical equipment provider’s stock valued at $324,000 after purchasing an additional 272 shares during the period. Jacobsen Capital Management grew its stake in shares of Boston Scientific by 4.9% in the 3rd quarter. Jacobsen Capital Management now owns 2,820 shares of the medical equipment provider’s stock valued at $236,000 after buying an additional 133 shares during the period. Highview Capital Management LLC DE increased its position in Boston Scientific by 17.2% in the 3rd quarter. Highview Capital Management LLC DE now owns 23,068 shares of the medical equipment provider’s stock valued at $1,933,000 after buying an additional 3,388 shares in the last quarter. Adams Diversified Equity Fund Inc. acquired a new position in Boston Scientific during the 3rd quarter worth approximately $17,908,000. Finally, Golden State Equity Partners boosted its holdings in Boston Scientific by 1.4% in the third quarter. Golden State Equity Partners now owns 10,614 shares of the medical equipment provider’s stock worth $889,000 after acquiring an additional 151 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Buying and Selling

In related news, EVP Jeffrey B. Mirviss sold 4,675 shares of Boston Scientific stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $104.25, for a total value of $487,368.75. Following the completion of the sale, the executive vice president now owns 28,454 shares of the company’s stock, valued at approximately $2,966,329.50. This trade represents a 14.11 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Wendy Carruthers sold 6,983 shares of the company’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $90.78, for a total transaction of $633,916.74. Following the sale, the executive vice president now directly owns 29,308 shares in the company, valued at approximately $2,660,580.24. This trade represents a 19.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 144,305 shares of company stock valued at $14,954,985. 0.50% of the stock is owned by company insiders.

Boston Scientific Trading Up 0.9 %

NYSE BSX opened at $101.61 on Thursday. The business’s fifty day moving average is $98.73 and its 200-day moving average is $89.95. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08 and a quick ratio of 1.02. The stock has a market capitalization of $149.96 billion, a price-to-earnings ratio of 81.29, a PEG ratio of 2.79 and a beta of 0.80. Boston Scientific Co. has a one year low of $65.52 and a one year high of $107.17.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, topping the consensus estimate of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. Equities research analysts predict that Boston Scientific Co. will post 2.85 EPS for the current year.

Wall Street Analyst Weigh In

BSX has been the subject of several recent research reports. Needham & Company LLC restated a “hold” rating on shares of Boston Scientific in a report on Thursday, February 6th. Stifel Nicolaus boosted their price target on shares of Boston Scientific from $100.00 to $115.00 and gave the company a “buy” rating in a research note on Thursday, February 6th. Piper Sandler raised their price objective on shares of Boston Scientific from $95.00 to $115.00 and gave the company an “overweight” rating in a research note on Monday, February 3rd. Canaccord Genuity Group boosted their target price on shares of Boston Scientific from $98.00 to $101.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. Finally, UBS Group raised their price target on shares of Boston Scientific from $105.00 to $130.00 and gave the company a “buy” rating in a research report on Friday, February 7th. Two investment analysts have rated the stock with a hold rating, twenty-one have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $107.39.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.